MannKind | MNKD - Current Assets


MannKind reported $240.48M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Adma Biologics USD 575.86M 47.66M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
MannKind USD 240.48M 5.24M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 707.96M 63.14M Sep/2026
Novo Nordisk DKK 31.89B 145.42B Jun/2026
Pfizer USD 45.01B 3.65B Sep/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Xencor USD 498.66M 24.55M Sep/2026